TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22967853

Group type: EXPERIMENTAL
Intervention: Temporary positive expiratory pressure (TPEP) combined with manually assisted breathing techniques for 10 consecutive days, twice a day for 20 minutes plus 15 minutes of TPEP.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group treated by manually assisted breathing techniques alone for 10 consecutive days.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Temporary positive expiratory pressure (TPEP) combined with manually assisted breathing techniques.
Number of subjects: 98
Study: 21681607

Group type: EXPERIMENTAL
Intervention: PD 0200390 administered 30 minutes earlier than standard dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 0
Study: 17356554

Group type: EXPERIMENTAL
Intervention: Probiotic capsules (3 capsules daily containing 10^9 CFU Lactobacillus acidophilus and Bifidobacterium longum, 10-15 mg fructo-oligosaccharide)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo capsules (3 capsules daily)
Number of subjects: 55
Study: 16950182

Group type: EXPERIMENTAL
Intervention: 10 mg of rosuvastatin
Number of subjects: 696

Group type: COMPARATOR
Intervention: 10 mg of atorvastatin
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: 20 mg of rosuvastatin
Number of subjects: 696

Group type: COMPARATOR
Intervention: 20 mg of atorvastatin
Number of subjects: 696
Study: 12707583

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging and ultrasonography
Number of subjects: 0
Study: 10676670

Group type: EXPERIMENTAL
Intervention: 600 IU vitamin E per day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonsmoking controls
Number of subjects: 22
Study: 9105488

Group type: EXPERIMENTAL
Intervention: Knowledge- and cognitive-behavioral skills-building intervention
Number of subjects: 513
Study: 8339135

Group type: EXPERIMENTAL
Intervention: Intermittent D-penicillamine therapy (250-750mg daily reduced to the same dose taken 1 week out of every 4)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Continuous D-penicillamine therapy
Number of subjects: 59
Study: 3522630

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral self-control therapy (adjunctive therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulant medications (standard treatment)
Number of subjects: 0
Study: 30161172

Group type: EXPERIMENTAL
Intervention: Test-and-treat intervention
Number of subjects: 63
Study: 29901369

Group type: EXPERIMENTAL
Intervention: DMPA (150 mg injections)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no DMPA injection)
Number of subjects: 28
Study: 25265770

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (patellar tendon graft subgroup)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.25% bupivacaine (patellar tendon graft subgroup)
Number of subjects: 100
Study: 21332611

Group type: EXPERIMENTAL
Intervention: Peer review intervention involving clinicians, hospital management, commissioners, and patients focusing on four specific evidence-based aspects of COPD care.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer review intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20410151

Group type: EXPERIMENTAL
Intervention: Enhanced rehabilitation (standard physiotherapy and nutritional interventions plus additional rehabilitation)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard physiotherapy and nutritional interventions (control group)
Number of subjects: 16
Study: 18618278

Group type: EXPERIMENTAL
Intervention: Diabetes history
Number of subjects: 33088

Group type: EXPERIMENTAL
Intervention: Diabetes history in lean men (BMI < 25 kg/m(2))
Number of subjects: 33088

Group type: EXPERIMENTAL
Intervention: Diabetes history in physically active men (3+ hours vigorous activity/week)
Number of subjects: 33088
Study: 16410276

Group type: EXPERIMENTAL
Intervention: Modified intensified insulin therapy (MII) using insulin pens and premixed insulin (30/70, 40/60, 50/50) in Group AI and Group AII.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Modified intensified insulin therapy (MII) in Group AII.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Conventional insulin therapy in Group B.
Number of subjects: 125
Study: 12838216

Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg) administered orally 15 hours and 3 hours before ERCP
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Placebo administered orally 15 hours and 3 hours before ERCP
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Both groups (corticosteroid and control)
Number of subjects: 1115
Study: 10846911

Group type: EXPERIMENTAL
Intervention: Diazepam premedication
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo premedication
Number of subjects: 87

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 87
Study: 9101144

Group type: EXPERIMENTAL
Intervention: Forward-viewing endoscope
Number of subjects: 45

Group type: COMPARATOR
Intervention: Side-viewing duodenoscope
Number of subjects: 45
Study: 1541306

Group type: EXPERIMENTAL
Intervention: Intramuscular phenobarbitone 7 mg.kg‐1
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2859779

Group type: EXPERIMENTAL
Intervention: acebutolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 60
Study: 31219150

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms (SNPs) in the major histocompatibility complex class I region (MHC I)
Number of subjects: 2440

Group type: EXPERIMENTAL
Intervention: HLA alleles
Number of subjects: 2440
Study: 28537957

Group type: EXPERIMENTAL
Intervention: ANtiPain intervention (n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard care (Control group, n = 19)
Number of subjects: 39
Study: 26772171

Group type: EXPERIMENTAL
Intervention: Multiple‐Modality and Mind‐Motor (M4) intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple‐Modality (M2) comparison group
Number of subjects: 0
Study: 24482343

Group type: EXPERIMENTAL
Intervention: Natural sign language community
Number of subjects: 2

Group type: COMPARATOR
Intervention: Homesign systems
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Population of interacting individuals in simulations
Number of subjects: 2
Study: 22289887

Group type: EXPERIMENTAL
Intervention: Nadroparin (3800 IU daily subcutaneous injections)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Medical surveillance alone
Number of subjects: 135
Study: 20847190

Group type: EXPERIMENTAL
Intervention: β-blocker treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 17626705

Group type: EXPERIMENTAL
Intervention: Advance Notification
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Risk
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Advocacy
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Advance Notification (2 weeks)
Number of subjects: 2400
Study: 15064424

Group type: EXPERIMENTAL
Intervention: CPTPPR
Number of subjects: 7

Group type: COMPARATOR
Intervention: CPT+15%
Number of subjects: 7
Study: 11447078

Group type: EXPERIMENTAL
Intervention: 450 mL black tea
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 900 mL black tea daily for 4 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 66

Group type: COMPARATOR
Intervention: 200 mg caffeine (equivalent oral dose)
Number of subjects: 66
Study: 9508353

Group type: EXPERIMENTAL
Intervention: Intravenous Ferrum Hausmann (iron dextrin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral ferrous fumarate
Number of subjects: 0
Study: 8293316

Group type: EXPERIMENTAL
Intervention: 100 mg/kg tyrosine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3191659

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 30
Study: 31978591

Group type: EXPERIMENTAL
Intervention: Hydrogel rectal spacer
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control plans (no spacer)
Number of subjects: 222
Study: 31542768

Group type: EXPERIMENTAL
Intervention: Self-aligning prosthesis
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard (more rigid) prosthesis
Number of subjects: 90
Study: 28320561

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine solution
Number of subjects: 114

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine solution
Number of subjects: 114
Study: 25878639

Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine
Number of subjects: 120

Group type: COMPARATOR
Intervention: High-dose cytarabine
Number of subjects: 120
Study: 22933432

Group type: EXPERIMENTAL
Intervention: Genetic testing and counseling
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (no genetic testing)
Number of subjects: 108
Study: 21689356

Group type: EXPERIMENTAL
Intervention: Preoperative mechanical bowel preparation (4 l of polyethylene glycol) plus a glycerine 5% enema (2 l)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Single glycerine 5% enema (2 l)
Number of subjects: 229
Study: 18087660

Group type: EXPERIMENTAL
Intervention: 75 mg risedronate on two consecutive days each month (2CDM)
Number of subjects: 1229

Group type: COMPARATOR
Intervention: 5 mg daily risedronate
Number of subjects: 1229
Study: 17078437

Group type: EXPERIMENTAL
Intervention: Acupuncture at the Back‐Shu and Front‐Mu points plus oral decoction
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral decoction alone
Number of subjects: 36
Study: 15274173

Group type: EXPERIMENTAL
Intervention: 5 mg escitalopram
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: All active treatments (5 mg, 10 mg, 20 mg escitalopram and 20 mg paroxetine)
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Escitalopram (5-20 mg)
Number of subjects: 839

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 839
Study: 11400897

Group type: EXPERIMENTAL
Intervention: Surgical extirpation (Group I)
Number of subjects: 79

Group type: COMPARATOR
Intervention: High-energy extracorporeal shock wave therapy (Group II)
Number of subjects: 79
Study: 9003206

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 micrograms twice daily
Number of subjects: 228

Group type: COMPARATOR
Intervention: Salbutamol, 200 micrograms four times daily
Number of subjects: 228
Study: 7685685

Group type: EXPERIMENTAL
Intervention: diclofenac/misoprostol 50mg/200 micrograms
Number of subjects: 670

Group type: COMPARATOR
Intervention: diclofenac 50mg
Number of subjects: 670
Study: 2892258

Group type: EXPERIMENTAL
Intervention: nizatidine 150 mg B.D.
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg nocte
Number of subjects: 275

Group type: COMPARATOR
Intervention: ranitidine 150 mg B.D.
Number of subjects: 275
Study: 31790779

Group type: EXPERIMENTAL
Intervention: Unyvero i60 ITI multiplex PCR (mPCR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard bacteriology
Number of subjects: 50
Study: 31495379

Group type: EXPERIMENTAL
Intervention: Nightlife Safety Plans (NSP)
Number of subjects: 959

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 959
Study: 28681715

Group type: EXPERIMENTAL
Intervention: Active tRNS of M1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study: 24750780

Group type: EXPERIMENTAL
Intervention: Soft silicone foam dressings applied to the sacrum and heels, changed every 3 days in the ICU.
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard PU prevention care during ED and ICU stay.
Number of subjects: 440
Study: 23649818

Group type: EXPERIMENTAL
Intervention: Biological allograft (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Synthetic ligament (group B)
Number of subjects: 40
Study: 22120091

Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Tolvaptan 45 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 19591515

Group type: EXPERIMENTAL
Intervention: Clozapine ODT 12.5 mg administered after a high-fat/calorie breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clozapine ODT 12.5 mg administered in a fasted state
Number of subjects: 24
Study: 16481384

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin-vindesine
Number of subjects: 0
Study: 14566480

Group type: EXPERIMENTAL
Intervention: Moist skin care with 3% urea lotion
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional dry skin care
Number of subjects: 88
Study: 10712990

Group type: EXPERIMENTAL
Intervention: Nutritional support (caloric supplementation for at least 2 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no nutritional support)
Number of subjects: 9
Study: 9021362

Group type: EXPERIMENTAL
Intervention: FSP + DNB speculum (group B, n = 110)
Number of subjects: 104

Group type: COMPARATOR
Intervention: IUI (group A, n = 92)
Number of subjects: 104
Study: 7505130

Group type: EXPERIMENTAL
Intervention: Single dose of hepatitis vaccine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Double dose of hepatitis vaccine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hepatitis vaccine (single or double dose)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single dose vaccine with revaccination if titer is negative or insufficiently high
Number of subjects: 28
Study: 3920170

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cimetidine 300 mg
Number of subjects: 71
Study: 29035942

Group type: EXPERIMENTAL
Intervention: Bilateral renal denervation (RDN) using therapeutic levels of ultrasound energy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sham treatment with bilateral application of diagnostic levels of ultrasound energy
Number of subjects: 81
Study: 27505217

Group type: EXPERIMENTAL
Intervention: High construal level prime with visual cue reminder
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: High construal level prime without visual cue reminder
Number of subjects: 176

Group type: COMPARATOR
Intervention: Low construal level prime with visual cue reminder
Number of subjects: 176

Group type: COMPARATOR
Intervention: Low construal level prime without visual cue reminder
Number of subjects: 176
Study: 24479729

Group type: EXPERIMENTAL
Intervention: PhysioDirect service
Number of subjects: 0
Study: 22580070

Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 20930343

Group type: EXPERIMENTAL
Intervention: Denture cleanser only
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Denture cleanser and mouth rinse
Number of subjects: 24
Study: 18583545

Group type: EXPERIMENTAL
Intervention: 3% alcohol-by-volume drink
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 7% alcohol-by-volume drink
Number of subjects: 32
Study: 16208640

Group type: EXPERIMENTAL
Intervention: Exercise intervention (specifics not provided)
Number of subjects: 0
Study: 12173797

Group type: EXPERIMENTAL
Intervention: InspirEase holding chamber
Number of subjects: 8

Group type: COMPARATOR
Intervention: E‐Z Spacer holding chamber
Number of subjects: 8
Study: 12507025

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 80
Study: 9732168

Group type: EXPERIMENTAL
Intervention: Topical calcipotriol (50 microgram/g) applied twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo ointment applied twice daily
Number of subjects: 19
Study: 7995005

Group type: EXPERIMENTAL
Intervention: 500 mg ordinary-release theophylline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3194866

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 1200 micrograms daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prednisone 12.5 mg daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 18
Study: 31714986

Group type: EXPERIMENTAL
Intervention: Bempedoic acid (180 mg)
Number of subjects: 779

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 779
Study: 28274812

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (33°C)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Therapeutic normothermia (36.8°C)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Drowning etiology
Number of subjects: 66

Group type: COMPARATOR
Intervention: Other respiratory etiologies
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 66
Study: 25906818

Group type: EXPERIMENTAL
Intervention: Diuretic (spironolactone 100 mg plus furosemide 20 mg daily)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet (maximum intake of 3 g of sodium per day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (placebo pill, maintain eating habits)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Diuretic (spironolactone plus furosemide)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 22803688

Group type: EXPERIMENTAL
Intervention: GSK2190915 (50-1000 mg single doses; 10-450 mg multiple doses; 10-200 mg in crossover design)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK2190915 (≥50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK2190915 (≥150 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21457576

Group type: EXPERIMENTAL
Intervention: Low-energy distal radius fractures (patients)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Controls (age-matched men without fractures)
Number of subjects: 44
Study: 18289576

Group type: EXPERIMENTAL
Intervention: 100 to 120 mg intravesical bacillus Calmette‐Guerin plus 100 mg para‐aminomethylbenzoic acid
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 50 to 60 mg bacillus Calmette‐Guerin plus 100 mg para‐aminomethylbenzoic acid
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 100 to 120 mg bacillus Calmette‐Guerin plus 2.0 gm epsilon aminocaproic acid
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 50 to 60 mg bacillus Calmette‐Guerin plus 2.0 gm epsilon aminocaproic acid
Number of subjects: 257

Group type: COMPARATOR
Intervention: 100 to 120 mg bacillus Calmette‐Guerin alone
Number of subjects: 257
Study: 16688994

Group type: EXPERIMENTAL
Intervention: Electro-scalp acupuncture (ESA) applied at points MS6, MS4, MS8, MS9, and MS14, with specific application based on unilateral or bilateral lesions, for 6 weeks.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Medopa orally, 125 mg 3 times/day for mild, 250 mg 3 times/day for moderate, and 250 mg 4 times/day for severe cases, for 6 weeks.
Number of subjects: 10
Study: 12955333

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (RLX60)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day (RLX120)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study: 11101199

Group type: EXPERIMENTAL
Intervention: tedisamil 100 mg b.i.d.
Number of subjects: 48

Group type: COMPARATOR
Intervention: atenolol 50 mg b.i.d.
Number of subjects: 48
Study: 8931841

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (3 +/- 1.3 hours of sleep)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal Night's Sleep (7.3 +/- 0.8 hours of sleep)
Number of subjects: 24
Study: 1382915

Group type: EXPERIMENTAL
Intervention: Lysine infusion (3-6 g of lysine intravenously followed by 0.3-1.9 g of lysine/kg over 1 hour)
Number of subjects: 15
Study: 31780006

Group type: EXPERIMENTAL
Intervention: Topical sesame oil
Number of subjects: 104

Group type: COMPARATOR
Intervention: Diclofenac gel
Number of subjects: 104
Study: 29031894

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation
Number of subjects: 0
Study: 25256135

Group type: EXPERIMENTAL
Intervention: Brief parent-focused behavioral management program
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Brief youth-focused strengths-building program
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Extended parent-focused second-stage programming
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Extended youth-focused second-stage programming
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SMART design
Number of subjects: 100
Study: 24745666

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine (10mg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 22192151

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of mononuclear bone marrow cells (mBMC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 20211293

Group type: EXPERIMENTAL
Intervention: Rivaroxaban, 20 mg once daily
Number of subjects: 14000

Group type: COMPARATOR
Intervention: Warfarin, dose-adjusted to a target INR of 2.5 (range 2.0-3.0)
Number of subjects: 14000
Study: 18035202

Group type: EXPERIMENTAL
Intervention: SC IFN‐beta1a 44 microg TIW (high-dose)
Number of subjects: 677

Group type: COMPARATOR
Intervention: IM IFN‐betala 30 microg QW (low-dose)
Number of subjects: 677
Study: 16253344

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (500-2500 mg/day)
Number of subjects: 251
Study: 11897605

Group type: EXPERIMENTAL
Intervention: Oral artesunate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin (DHA)
Number of subjects: 18